Here's what Johnson & Johnson reported compared with what analysts surveyed by Bloomberg were expecting:Still, J&J's net earnings of $1.39 a share were down 14.2% compared to the same period last year as the conglomerate recorded litigation expenses of $423 million in the first-quarter. Last year, its net earnings were $1.60 a share.
"We note J&J waited to raise guidance until 2Q18 last year, so today's guidance raise suggests a higher degree of confidence in the achievability of guidance targets," said Morgan Stanley analyst David Lewis in a note to clients out Tuesday morning.in mid-December alleged Johnson & Johnson knew for decades without disclosing to regulators or the public that some of its products contained small amounts of asbestos. Johnson & Johnson refuted the report's findings.
to produce documents related to the safety of the company's baby powder and other talc-containing products. Wall Street is essentially split between bullish and neutral. Of those analysts surveyed by Bloomberg, 11 said"buy," 10 were"neutral," and one suggested"sell."Now read more markets coverage from Markets Insider and Business Insider: